ImmunityBio, Inc. IBRX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s operating cash flow?
- ImmunityBio, Inc. (IBRX) reported operating cash flow of -$75.36M in Q1 2026.
- How has ImmunityBio, Inc.'s operating cash flow changed year-over-year?
- ImmunityBio, Inc.'s operating cash flow increased by 12.3% year-over-year, from -$85.91M to -$75.36M.
- What is the long-term trend for ImmunityBio, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s operating cash flow has grown at a 2.7% compound annual growth rate (CAGR), from -$274.42M to -$304.94M.
- What does operating cash flow mean?
- The amount of cash a company generates from its primary business activities.
- How do you interpret operating cash flow?
- Higher values indicate strong operational cash generation, while negative values suggest the company is burning cash to sustain operations.
- How does operating cash flow compare across companies?
- Biotech firms in clinical stages typically show negative operating cash flow due to high R&D spending.